Opinion|Videos|November 19, 2024
Options for CRC Screening and Need for Patient- Centered Decision-Making
Author(s)Vivek Kaul, MD
Key Takeaways
- Stool-based tests, such as FIT and gFOBT, detect occult blood in stool, serving as non-invasive screening options for colorectal cancer.
- Blood-based tests focus on identifying circulating tumor DNA or specific biomarkers, offering a less invasive alternative to traditional screening methods.
Vivek Kaul, MD, discusses the various options available for colorectal cancer screening, providing an overview of stool-based tests, blood-based tests, colonoscopy, and emerging screening methods.
Advertisement
- What are the options available for colorectal cancer screening? Could you briefly provide an overview of each of the following?
- Stool-based tests
- Blood-based tests
- Colonoscopy
Advertisement
Related to this article
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
52-Week Litifilimab Data in Cutaneous Lupus Erythematosus
3
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
4
Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH
5